Treatment regimen recommended for resistant tuberculosis consists of various drugs and these drugs are
prescribed for at least 12-15 months. Such a long duration therapy and high dose of antibiotics result in adverse
drug reactions (ADRs). ADRs may lead to various complications in disease management like replacement of drugs,
dose increment, therapy withdrawal, etc. Linezolid is one of those drugs, practiced as an anti-mycobacterial agent
and it is an important member of drug regimen for MDR and XDR tuberculosis. Linezolid is a broad spectrum antibiotic
known for its unique mechanism of inhibition of resistant pathogenic strains. However, it causes serious adverse effects like
thrombocytopenia, optic neuropathy, peripheral neuropathy, lactic acidosis, etc. Literature suggests that Linezolid can cause severe ADRs
which affect patient compliance and hinder in therapy to a larger extent. Recent studies confirm the possibility of ADRs to be predicted
with genetic make-up of individuals. To effectively deliver the available treatment regimen and ensure patient compliance, it is important
to manage ADRs more efficiently. The role of pharmacogenomics in reducing adverse drug effects has been recently explored. In the
present review, we discussed about Linezolid induced adverse drug reactions, mechanisms and genetic associations.
Keywords: Adverse drug reactions, anti-tuberculosis drugs, drug interactions, linezolid, optic neuropathy, thrombocytopenia.
Rights & PermissionsPrintExport